Home > Neurology > EHC 2022 > Intervention > Onabotulinumtoxin A effective in older patients with chronic migraine

Onabotulinumtoxin A effective in older patients with chronic migraine

Presented By
Dr Raffaele Ornello , University of L’Aquila, Italy
Conference
EHC 2022
Doi
https://doi.org/10.55788/74072edb
In a real-world, European, multicentre study that retrospectively evaluated a large case series of elderly patients with chronic migraine, onabotulinumtoxin A (OBT-A) provided a significant benefit in the first 3 cycles of treatment. This benefit was similar to that in younger patients. This is an important finding for a patient population that is underserved in terms of treatment options, argued Dr Raffaele Ornello (University of L’Aquila, Italy), who presented the study results [1]. Migraine in older patients, defined here as ≥65 years, is rare, and chronic migraine even rarer. Treatment is complicated by comorbidity, and viable treatment options are warranted for older patients with chronic migraine. This study evaluated OBT-A as preventative therapy in this population to see whether it is as effective as in younger chronic migraine patients (<65 years). The post-hoc analysis prospectively collected real-world data at 16 European headache centres. It...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on